Your session is about to expire
← Back to Search
Radiation Therapy
SABR for Kidney Cancer
N/A
Recruiting
Led By Andrew McPartlin, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histological or radiological diagnosis of renal tumor
ECOG performance status of 0-3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial will investigate whether the use of stereotactic ablative radiosurgery (SABR) is a non-invasive, effective alternative treatment for renal tumors in patients who are not suitable candidates for surgery.
Who is the study for?
This trial is for patients with a solid kidney mass suitable for SABR treatment, specifically those who have primary RCC or metastasis up to 6cm. It's aimed at people who are high-risk for surgery or have declined it, and can still perform daily activities (ECOG status 0-3). Those with multiple active metastases, recent systemic therapy, prior overlapping abdominal radiotherapy, end-stage renal failure, or certain genetic syndromes cannot participate.Check my eligibility
What is being tested?
The study is testing Stereotactic Ablative Radiotherapy (SABR) as a non-surgical option for treating renal tumors. Patients will receive high-dose radiation targeting the tumor while sparing surrounding organs. They'll be monitored before and after treatment and every four months over two years to assess their quality of life and changes in the tumor through standard imaging.See study design
What are the potential side effects?
Potential side effects of SABR may include fatigue, skin reactions at the treatment site, nausea, damage to nearby organs such as intestines or liver due to radiation exposure. Long-term risks could involve development of secondary cancers from radiation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidney tumor was confirmed by a biopsy or scan.
Select...
I am able to care for myself but may not be able to do heavy physical work.
Select...
I have a kidney tumor smaller than 6cm suitable for targeted radiation.
Select...
My condition is considered too risky for surgery or I have chosen not to undergo surgery.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To evaluate the radiation induced renal impairments in patients receiving SABR.
Secondary outcome measures
2-year Local recurrence rate
Chronic Kidney Disease Stage Progression
Incidence of acute and late toxicities
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Stereotactic Ablative RadiotherapyExperimental Treatment1 Intervention
Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,472 Previous Clinical Trials
484,959 Total Patients Enrolled
Andrew McPartlin, MDPrincipal InvestigatorThe Princess Margaret Cancer Foundation
1 Previous Clinical Trials
173 Total Patients Enrolled
Joelle Helou, MDPrincipal InvestigatorUniversity Health Network--Princess Margaret Cancer Centre
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney tumor was confirmed by a biopsy or scan.I am able to care for myself but may not be able to do heavy physical work.I have a kidney tumor smaller than 6cm suitable for targeted radiation.My condition is considered too risky for surgery or I have chosen not to undergo surgery.I have a genetic condition like Von Hippel-Lindau disease or Polycystic Kidney Disease.I've had radiotherapy on my abdomen that affected my kidney with high doses.My kidney function is severely reduced.I have 5 or more active cancer spread sites.I haven't had any systemic therapy except hormone therapy in the last 6 days.
Research Study Groups:
This trial has the following groups:- Group 1: Stereotactic Ablative Radiotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the scope of patients receiving treatment as part of this experiment?
"Affirmative. Clinicaltrials.gov confirms that this clinical trial, which was first made public on the 1st of November 2018, is still searching for participants. There are 30 spots available to be filled at two different sites."
Answered by AI
Has enrollment opened for this experiment yet?
"The clinical trial, which was initially launched on November 1st 2018, is still recruiting patients according to the information found on clinicaltrials.gov. The last update occurred October 17th 2022."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger